We, therefore, suggest that prior to broadly adopting this imaging technique, it must be borne in mind that a small proportion of prostate carcinomas exhibit no or only minimal uptake on PSMA PET/CT. This evidence concerns the gene FOLH1 and prostate carcinoma.